JP2009504591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504591A5 JP2009504591A5 JP2008525474A JP2008525474A JP2009504591A5 JP 2009504591 A5 JP2009504591 A5 JP 2009504591A5 JP 2008525474 A JP2008525474 A JP 2008525474A JP 2008525474 A JP2008525474 A JP 2008525474A JP 2009504591 A5 JP2009504591 A5 JP 2009504591A5
- Authority
- JP
- Japan
- Prior art keywords
- heteroaryl
- formula
- pharmaceutically acceptable
- acceptable salt
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 10
- 125000002619 bicyclic group Chemical group 0.000 claims 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 239000011593 sulfur Chemical group 0.000 claims 6
- 229910052717 sulfur Chemical group 0.000 claims 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- VEEPFOJGVUXDRX-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(4-fluorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=C(F)C=C1 VEEPFOJGVUXDRX-UHFFFAOYSA-N 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 150000003536 tetrazoles Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0516464.5 | 2005-08-10 | ||
| GB0516464A GB0516464D0 (en) | 2005-08-10 | 2005-08-10 | Novel compounds |
| GB0607736.6 | 2006-04-19 | ||
| GB0607736A GB0607736D0 (en) | 2006-04-19 | 2006-04-19 | Novel compounds |
| GB0614569.2 | 2006-07-21 | ||
| GB0614569A GB0614569D0 (en) | 2006-07-21 | 2006-07-21 | Novel compounds |
| PCT/EP2006/007865 WO2007017261A1 (en) | 2005-08-10 | 2006-08-08 | Xanthine derivatives as selective hm74a agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009504591A JP2009504591A (ja) | 2009-02-05 |
| JP2009504591A5 true JP2009504591A5 (enExample) | 2012-10-11 |
| JP5112316B2 JP5112316B2 (ja) | 2013-01-09 |
Family
ID=37189397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525475A Withdrawn JP2009504592A (ja) | 2005-08-10 | 2006-08-08 | 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体 |
| JP2008525474A Expired - Fee Related JP5112316B2 (ja) | 2005-08-10 | 2006-08-08 | 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525475A Withdrawn JP2009504592A (ja) | 2005-08-10 | 2006-08-08 | 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8143264B2 (enExample) |
| EP (3) | EP1912992A1 (enExample) |
| JP (2) | JP2009504592A (enExample) |
| KR (2) | KR20080038396A (enExample) |
| AR (1) | AR055369A1 (enExample) |
| AT (1) | ATE487719T1 (enExample) |
| AU (2) | AU2006278215A1 (enExample) |
| BR (2) | BRPI0615145A2 (enExample) |
| CA (2) | CA2618963A1 (enExample) |
| CR (2) | CR9748A (enExample) |
| CY (1) | CY1111757T1 (enExample) |
| DE (1) | DE602006018151D1 (enExample) |
| DK (1) | DK1912991T3 (enExample) |
| EA (2) | EA014556B1 (enExample) |
| ES (1) | ES2401128T3 (enExample) |
| HR (1) | HRP20100725T1 (enExample) |
| IL (2) | IL189083A0 (enExample) |
| MA (2) | MA29692B1 (enExample) |
| MX (2) | MX2008001931A (enExample) |
| MY (1) | MY142067A (enExample) |
| NO (2) | NO20081212L (enExample) |
| NZ (1) | NZ565494A (enExample) |
| PE (1) | PE20070405A1 (enExample) |
| PL (1) | PL1912991T3 (enExample) |
| PT (1) | PT1912991E (enExample) |
| SI (1) | SI1912991T1 (enExample) |
| TW (1) | TW200800217A (enExample) |
| WO (2) | WO2007017262A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
| SI1781657T1 (sl) * | 2004-02-14 | 2013-07-31 | Glaxosmithkline Intellectual Property Development Limited | Zdravila z aktivnostjo na receptor hm74a |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| EP1912992A1 (en) * | 2005-08-10 | 2008-04-23 | SmithKline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
| CA2656039A1 (en) | 2006-06-23 | 2007-12-27 | Incyte Corporation | Purinone derivatives as hm74a agonists |
| AR061626A1 (es) | 2006-06-23 | 2008-09-10 | Incyte Corp | Derivados de purinona como agonistas de hm74a |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| PL2370440T3 (pl) | 2008-12-08 | 2015-05-29 | Glaxosmithkline Llc | Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób |
| JP2013503135A (ja) | 2009-08-26 | 2013-01-31 | サノフイ | 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR101799429B1 (ko) | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| PH12013500301A1 (en) * | 2010-08-16 | 2013-03-25 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
| US8580825B2 (en) * | 2010-09-23 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2855455B1 (en) * | 2012-05-30 | 2017-11-08 | F. Hoffmann-La Roche AG | Triazolo compounds as pde10 inhibitors |
| DK2970303T6 (en) * | 2013-03-15 | 2018-10-08 | Hydra Biosciences Inc | SUBSTITUTED XANTHINES AND PROCEDURES FOR USING IT |
| JP6417403B2 (ja) | 2013-05-10 | 2018-11-07 | ギリアド アポロ， エルエルシー | Ａｃｃ阻害剤及びその使用 |
| EP2994139B1 (en) | 2013-05-10 | 2019-04-10 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| EP2994138A4 (en) * | 2013-05-10 | 2016-12-28 | Nimbus Apollo Inc | ACC-HEMMER AND USES THEREOF |
| BR112015028173A2 (pt) | 2013-05-10 | 2017-07-25 | Nimbus Apollo Inc | inibidores de acc e usos dos mesmos |
| CN105646492B (zh) * | 2014-11-14 | 2019-04-09 | 中国医学科学院药物研究所 | 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途 |
| DE102017000359A1 (de) | 2016-08-26 | 2018-03-01 | Bihl+Wiedemann Gmbh | Diagnose-Repeater für AS-Interface Netze |
| CN110461838B (zh) * | 2017-03-07 | 2022-05-06 | 豪夫迈·罗氏有限公司 | 噁二唑瞬时受体电位通道抑制剂 |
| CN112724141A (zh) * | 2021-01-21 | 2021-04-30 | 南京艾美斐生物医药科技有限公司 | 一种gpr109a蛋白受体抑制剂及其制备和应用 |
| TW202342465A (zh) * | 2022-02-03 | 2023-11-01 | 美商Ｄ Ｅ 蕭爾研究有限公司 | 作為trpa1抑制劑之n3經取代脲嘧啶化合物 |
| CN120835783A (zh) * | 2023-01-30 | 2025-10-24 | D·E·萧尔研究有限责任公司 | 作为trpa1抑制剂的双环酰亚胺化合物 |
| AR133217A1 (es) * | 2023-07-10 | 2025-09-10 | De Shaw Res Llc | Inhibidores de trpa1 bicíclicos y monocíclicos |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2797220A (en) * | 1954-12-02 | 1957-06-25 | Univ Michigan | Substituted paraxanthines |
| GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| NZ240644A (en) | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
| WO1993016699A1 (en) | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
| ATE230990T1 (de) | 1992-03-04 | 2003-02-15 | Cell Therapeutics Inc | Enantiomere hydroxylierte xanthinverbindungen |
| US6469017B1 (en) * | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
| US5473070A (en) | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
| US5804584A (en) * | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
| US6693105B1 (en) * | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| IL109161A0 (en) | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
| US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
| AU6702894A (en) | 1993-04-09 | 1994-11-08 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| AU1868195A (en) | 1994-01-28 | 1995-08-15 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6103730A (en) * | 1994-03-24 | 2000-08-15 | Cell Therapeutics, Inc. | Amine substituted compounds |
| US6878715B1 (en) * | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| US6780865B1 (en) * | 1994-02-18 | 2004-08-24 | Cell Therapeutics, Inc. | Compounds having selective hydrolytic potentials |
| EP0746557A4 (en) * | 1994-02-18 | 1997-05-02 | Cell Therapeutics Inc | INTRACELLULAR SIGNALING MEDIATORS |
| US5807861A (en) * | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
| US6323201B1 (en) * | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| JP2002541258A (ja) | 1999-04-09 | 2002-12-03 | セル セラピューティクス インコーポレーテッド | インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法 |
| US20030207901A1 (en) * | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| US6586429B2 (en) * | 2000-11-29 | 2003-07-01 | Cell Therapeutics, Inc. | Tricyclic fused xanthine compounds and their uses |
| HU230384B1 (hu) * | 2001-02-24 | 2016-03-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként |
| US20040254224A1 (en) | 2001-04-11 | 2004-12-16 | Foord Steven Michael | Medicaments |
| EP1404675B1 (en) * | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| EP1338595B1 (en) * | 2002-02-25 | 2006-05-03 | Eisai Co., Ltd. | Xanthine derivatives as DPP-IV inhibitors |
| US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| CN1227492C (zh) * | 2003-03-11 | 2005-11-16 | 张跃 | 一种吸收式空调主体 |
| GB0319124D0 (en) * | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| SI1781657T1 (sl) * | 2004-02-14 | 2013-07-31 | Glaxosmithkline Intellectual Property Development Limited | Zdravila z aktivnostjo na receptor hm74a |
| WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
| BRPI0517458A (pt) * | 2004-10-22 | 2008-10-07 | Smithkline Beecham Corp | derivados da xantina com atividade para o receptor hm74a |
| US20090209561A1 (en) * | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
| JP2008530074A (ja) * | 2005-02-14 | 2008-08-07 | スミスクライン・ビーチャム・コーポレイション | Ｈｍ７４ａ受容体アゴニストとしてのアントラニル酸誘導体 |
| GB0516462D0 (en) * | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
| EP1912992A1 (en) * | 2005-08-10 | 2008-04-23 | SmithKline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
| DE102008009758A1 (de) * | 2008-02-18 | 2009-08-20 | Beiersdorf Ag | Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite |
| PL2370440T3 (pl) | 2008-12-08 | 2015-05-29 | Glaxosmithkline Llc | Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób |
-
2006
- 2006-08-08 EP EP06776699A patent/EP1912992A1/en not_active Withdrawn
- 2006-08-08 CA CA002618963A patent/CA2618963A1/en not_active Abandoned
- 2006-08-08 HR HR20100725T patent/HRP20100725T1/hr unknown
- 2006-08-08 ES ES10172674T patent/ES2401128T3/es active Active
- 2006-08-08 DE DE602006018151T patent/DE602006018151D1/de active Active
- 2006-08-08 EA EA200800555A patent/EA014556B1/ru not_active IP Right Cessation
- 2006-08-08 NZ NZ565494A patent/NZ565494A/en not_active IP Right Cessation
- 2006-08-08 TW TW095128952A patent/TW200800217A/zh unknown
- 2006-08-08 CA CA002626723A patent/CA2626723A1/en not_active Abandoned
- 2006-08-08 EP EP10172674A patent/EP2272848B1/en active Active
- 2006-08-08 MY MYPI20063833A patent/MY142067A/en unknown
- 2006-08-08 WO PCT/EP2006/007869 patent/WO2007017262A1/en not_active Ceased
- 2006-08-08 BR BRPI0615145-0A patent/BRPI0615145A2/pt not_active Application Discontinuation
- 2006-08-08 MX MX2008001931A patent/MX2008001931A/es active IP Right Grant
- 2006-08-08 MX MX2008001929A patent/MX2008001929A/es not_active Application Discontinuation
- 2006-08-08 KR KR1020087005724A patent/KR20080038396A/ko not_active Withdrawn
- 2006-08-08 US US12/063,434 patent/US8143264B2/en not_active Expired - Fee Related
- 2006-08-08 US US12/063,432 patent/US20100179128A1/en not_active Abandoned
- 2006-08-08 SI SI200630916T patent/SI1912991T1/sl unknown
- 2006-08-08 WO PCT/EP2006/007865 patent/WO2007017261A1/en not_active Ceased
- 2006-08-08 AU AU2006278215A patent/AU2006278215A1/en not_active Abandoned
- 2006-08-08 DK DK06763016.0T patent/DK1912991T3/da active
- 2006-08-08 EA EA200800564A patent/EA200800564A1/ru unknown
- 2006-08-08 BR BRPI0614270-2A patent/BRPI0614270A2/pt not_active IP Right Cessation
- 2006-08-08 KR KR1020087005717A patent/KR20080034993A/ko not_active Ceased
- 2006-08-08 JP JP2008525475A patent/JP2009504592A/ja not_active Withdrawn
- 2006-08-08 PT PT06763016T patent/PT1912991E/pt unknown
- 2006-08-08 PL PL06763016T patent/PL1912991T3/pl unknown
- 2006-08-08 AR ARP060103459A patent/AR055369A1/es unknown
- 2006-08-08 AT AT06763016T patent/ATE487719T1/de active
- 2006-08-08 JP JP2008525474A patent/JP5112316B2/ja not_active Expired - Fee Related
- 2006-08-08 AU AU2006278216A patent/AU2006278216A1/en not_active Abandoned
- 2006-08-08 PE PE2006000963A patent/PE20070405A1/es not_active Application Discontinuation
- 2006-08-08 EP EP06763016A patent/EP1912991B1/en active Active
-
2008
- 2008-01-28 IL IL189083A patent/IL189083A0/en unknown
- 2008-01-28 IL IL189081A patent/IL189081A0/en unknown
- 2008-02-08 MA MA30628A patent/MA29692B1/fr unknown
- 2008-02-08 MA MA30629A patent/MA29693B1/fr unknown
- 2008-02-21 CR CR9748A patent/CR9748A/es not_active Application Discontinuation
- 2008-02-21 CR CR9749A patent/CR9749A/es not_active Application Discontinuation
- 2008-03-07 NO NO20081212A patent/NO20081212L/no not_active Application Discontinuation
- 2008-03-07 NO NO20081211A patent/NO20081211L/no not_active Application Discontinuation
-
2011
- 2011-01-12 CY CY20111100033T patent/CY1111757T1/el unknown
- 2011-04-18 US US13/088,962 patent/US20110257205A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009504591A5 (enExample) | ||
| JP2005500311A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2008523069A5 (enExample) | ||
| JP2020502049A5 (enExample) | ||
| JP2015535832A5 (enExample) | ||
| JP2007503405A5 (enExample) | ||
| JP2007503487A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2009515988A5 (enExample) | ||
| JP2010504286A5 (enExample) | ||
| CY1114932T1 (el) | Αντιπαρασιτικοι παραγοντες | |
| JP2012526728A5 (enExample) | ||
| JP2008510808A5 (enExample) | ||
| JP2005511532A5 (enExample) | ||
| JP2018529650A5 (enExample) | ||
| JP2007523139A5 (enExample) | ||
| JP2008505194A5 (enExample) | ||
| JP2019532092A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| JP2010520851A5 (enExample) | ||
| AR035759A1 (es) | Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
| JP2016535769A5 (enExample) | ||
| JP2006509842A5 (enExample) | ||
| JP2015521192A5 (enExample) |